Back to all studies
CompletedNCT00728195

3 Fixed Doses of JNJ-37822681 Administered Twice Daily for schizophrenia

This study is completed in Bulgaria, in Estonia, in Lithuania, .... It is testing 3 Fixed Doses of JNJ-37822681 Administered Twice Daily for schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether JNJ-37822681 may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may receive JNJ-37822681, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Bulgaria, in Estonia, and in Lithuania.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNovember 2008
Recruitment status
Completed
Enrollment listed in the registry
498
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Bulgaria, Estonia, Lithuania, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00728195
Official title
A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of JNJ-37822681 Administered Twice Daily in Subjects With Schizophrenia

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00728195. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Bulgaria · 5 sites
  • Burgas
    Burgas
    Site status: Not listed — confirm with the team
  • Pazardzhik
    Pazardzhik
    Site status: Not listed — confirm with the team
  • Radnevo
    Radnevo
    Site status: Not listed — confirm with the team
  • Rousse
    Rousse
    Site status: Not listed — confirm with the team
  • Sofia
    Sofia
    Site status: Not listed — confirm with the team
Estonia · 2 sites
  • Tallinn
    Tallinn
    Site status: Not listed — confirm with the team
  • Tartu
    Tartu
    Site status: Not listed — confirm with the team
Lithuania · 2 sites
  • Kaunas
    Kaunas
    Site status: Not listed — confirm with the team
  • Vilnius
    Vilnius
    Site status: Not listed — confirm with the team
Malaysia · 3 sites
  • Johor Bahru
    Johor Bahru
    Site status: Not listed — confirm with the team
  • Kuala Lumpur
    Kuala Lumpur
    Site status: Not listed — confirm with the team
  • Kuching
    Kuching
    Site status: Not listed — confirm with the team
Romania · 7 sites
  • Arad
    Arad
    Site status: Not listed — confirm with the team
  • Brasov
    Brasov
    Site status: Not listed — confirm with the team
  • Bucharest
    Bucharest
    Site status: Not listed — confirm with the team
  • Jebel
    Jebel
    Site status: Not listed — confirm with the team
  • Oradea
    Oradea
    Site status: Not listed — confirm with the team
  • Sibiu
    Sibiu
    Site status: Not listed — confirm with the team
  • Tg Mures
    Tg Mures
    Site status: Not listed — confirm with the team
Russia · 9 sites
  • Ekaterinburg Na
    Ekaterinburg Na
    Site status: Not listed — confirm with the team
  • Moscow
    Moscow
    Site status: Not listed — confirm with the team
  • Moscow Russia
    Moscow Russia
    Site status: Not listed — confirm with the team
  • N Novgorod Na
    N Novgorod Na
    Site status: Not listed — confirm with the team
  • Saint Petersburg
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • Samara
    Samara
    Site status: Not listed — confirm with the team
  • Saratov
    Saratov
    Site status: Not listed — confirm with the team
  • Tomsk Na
    Tomsk Na
    Site status: Not listed — confirm with the team
  • Yaroslavl
    Yaroslavl
    Site status: Not listed — confirm with the team
South Africa · 3 sites
  • Cape Town
    Cape Town
    Site status: Not listed — confirm with the team
  • Centurion Gauteng
    Centurion Gauteng
    Site status: Not listed — confirm with the team
  • Pretoria
    Pretoria
    Site status: Not listed — confirm with the team
South Korea · 4 sites
  • Gwangju
    Gwangju
    Site status: Not listed — confirm with the team
  • Gyeongsangnam-Do
    Gyeongsangnam-Do
    Site status: Not listed — confirm with the team
  • Incheon
    Incheon
    Site status: Not listed — confirm with the team
  • Seoul
    Seoul
    Site status: Not listed — confirm with the team
Taiwan · 3 sites
  • Hualien City
    Hualien City
    Site status: Not listed — confirm with the team
  • Kaohsiung City
    Kaohsiung City
    Site status: Not listed — confirm with the team
  • Taipei
    Taipei
    Site status: Not listed — confirm with the team
Ukraine · 7 sites
  • Dnipropetrovsk
    Dnipropetrovsk
    Site status: Not listed — confirm with the team
  • Donetsk
    Donetsk
    Site status: Not listed — confirm with the team
  • Kharkiv
    Kharkiv
    Site status: Not listed — confirm with the team
  • Kherson
    Kherson
    Site status: Not listed — confirm with the team
  • Kiev
    Kiev
    Site status: Not listed — confirm with the team
  • Odesa
    Odesa
    Site status: Not listed — confirm with the team
  • Simferopol
    Simferopol
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving JNJ-37822681, Olanzapine, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

Who might this study be for?

This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me